Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® SARASOTA, Fla., May 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent,...